Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | CA9 | Q16790 | 2/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL176369 | 0.90 | CA12 (0.71) | CA12CA1CA2CA9CA14 | |
| Terephthalic Acid SCHEMBL28552075 | 0.85 | CA1 (0.65) | CA12CA1CA2CA9CA14 | |
| SCHEMBL22767273 | 0.83 | TDP1 (0.53) | CA12CA1CA2CA9CA14 | |
| SCHEMBL7872582 | 0.83 | CA12 (0.63) | CA12CA1CA2CA9CA14 | |
| SCHEMBL2832918 | 0.83 | CA1 (0.63) | CA12CA1CA2CA9CA14 | |
| SCHEMBL2908935 | 0.82 | RAB9A (0.49) | CA12CA1CA2CA9CA14 | |
| SCHEMBL9960375 | 0.82 | CA1 (0.58) | CA12CA1CA2CA9CA14 | |
| SCHEMBL11410746 | 0.81 | CA12 (0.66) | CA12CA1CA2CA9CA14 | |
| SCHEMBL576636 | 0.81 | NPC1 (0.69) | CA12CA1CA2CA9CA14 | |
| SCHEMBL14441122 | 0.81 | CA12 (0.56) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546421-B1 | Oncogenic-RAS-signal dependent lethal compounds | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546421-B1 | Oncogenic-RAS-signal dependent lethal compounds | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-10-01 | — | — | US | disclosed |
| EP-1975256-B1 | Modified oligonucleotides for mismatch discrimination | EPOCH BIOSCIENCES INC (US) | 2012-07-11 | — | — | EP | disclosed |
| EP-1975256-B1 | Modified oligonucleotides for mismatch discrimination | EPOCH BIOSCIENCES INC (US) | 2012-07-11 | — | — | EP | disclosed |
| EP-1261616-B1 | MODIFIED OLIGONUCLEOTIDES FOR MISMATCH DISCRIMINATION | EPOCH BIOSCIENCES INC (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-1261616-B1 | MODIFIED OLIGONUCLEOTIDES FOR MISMATCH DISCRIMINATION | EPOCH BIOSCIENCES INC (US) | 2010-08-18 | — | — | EP | disclosed |
| US-7751982-B2 | TM leveling methods | ELITECH HOLDING B.V. (NL) | 2010-07-06 | — | — | US | disclosed |
| US-7751982-B2 | TM leveling methods | ELITECH HOLDING B.V. (NL) | 2010-07-06 | — | — | US | disclosed |
| US-7715989-B2 | Systems and methods for predicting oligonucleotide melting temperature (TmS) | ELITECH HOLDING B.V. (NL) | 2010-05-11 | — | — | US | disclosed |
| US-20100081654-A1 | Oncogenic-RAS-signal dependent lethal compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-01 | — | — | US | disclosed |
| US-20060003349-A1 | Tm leveling compositions | EPOCH BIOSCIENCES, INC. (US) | 2006-01-05 | — | — | US | disclosed |
| US-6949367-B1 | Modified oligonucleotides for mismatch discrimination | EPOCH PHARMACEUTICALS, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| EP-1537488-A2 | SYSTEMS AND METHODS FOR PREDICTING OLIGONUCLEOTIDE MELTING TEMPERATURES (TMS) | Epoch Biosciences, Inc. (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20050075491-A1 | TM leveling methods | EPOCH BIOSCIENCES, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| US-6683173-B2 | CONJUGATING OLIGONUCLEOTIDE WITH 3-SUBSTITUTED PYRAZOLO(3,4-D)PYRIMIDINES AND/OR 5-SUBSTITUTED PYRIMIDINE MINOR GROOVE BINDER | EPOCH BIOSCIENCES, INC. | 2004-01-27 | — | — | US | disclosed |
| US-20030235822-A1 | Systems and methods for predicting oligonucleotide melting temperature (TmS) | EPOCH BIOSCIENCES, INC. | 2003-12-25 | — | — | US | disclosed |
| WO-2003107144-A2 | SYSTEMS AND METHODS FOR PREDICTING OLIGONUCLEOTIDE MELTING TEMPERATURES (TMS) | EPOCH BIOSCIENCES, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| US-20030224359-A1 | TMLEVELING METHODS | EPOCH BIOSCIENCES, INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1261616-A2 | MODIFIED OLIGONUCLEOTIDES FOR MISMATCH DISCRIMINATION | Epoch Biosciences, Inc. (US) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001064958-A2 | MODIFIED OLIGONUCLEOTIDES FOR MISMATCH DISCRIMINATION | EPOCH BIOSCIENECS, INC. (US) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081654-A1 | Oncogenic-RAS-signal dependent lethal compounds | HRAS, KRAS, NRAS | CA12 4177/4885CA1 3747/4885CA2 3593/4885 |
| US-20060003349-A1 | Tm leveling compositions | RNGTT, TYMS, NT5C3B | CA12 4863/4885CA1 4800/4885CA2 4837/4885 |
| US-20050075491-A1 | TM leveling methods | RNGTT, TYMS, NT5C3B | CA12 4819/4885CA1 4802/4885CA2 4827/4885 |
| US-20030224359-A1 | TMLEVELING METHODS | PTBP3, RNGTT, DTYMK | CA12 4858/4885CA1 4849/4885CA2 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.